BioMarin Pharmaceutical Inc. (BMRN) — Analyst outlook / Analyst consensus target is. Based on 41 analyst ratings, the consensus is bullish — 28 Buy, 13 Hold.
The consensus price target is $86.60 (low: $60.00, high: $105.00), representing an upside of 56.1% from the current price $55.47.
Analysts estimate Earnings Per Share (EPS) of $2.26 and revenue of $2.82B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $2.13 vs est $2.26 (missed -5.7%). 2025: actual $1.82 vs est $2.21 (missed -17.6%). Analyst accuracy: 86%.
BMRN Stock — 12-Month Price Forecast
$86.60
▲ +56.12% Upside
Average Price Target
Based on 41 Wall Street analysts offering 12-month price targets for BioMarin Pharmaceutical Inc., the average price target is $86.60, with a high forecast of $105.00, and a low forecast of $60.00.
The average price target represents a +56.12% change from the last price of $55.47.
Highest Price Target
$105.00
Average Price Target
$86.60
Lowest Price Target
$60.00
BMRN Analyst Ratings
Buy
Based on 41 analysts giving stock ratings to BioMarin Pharmaceutical Inc. in the past 3 months
EPS Estimates — BMRN
86%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $2.13
vs Est $2.26
▼ 6.0% off
2025
Actual $1.82
vs Est $2.21
▼ 21.4% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is declining. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — BMRN
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $2.854B
vs Est $2.818B
▲ 1.3% off
2025
Actual $3.221B
vs Est $3.179B
▲ 1.3% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
